Pipeline

Our focus on innovative product development for musculoskeletal pain and pain adjacencies is motivated by the unmet need in this space.

Advancing therapies for pain relief

Our pipeline reflects our deep commitment to advancing the science of non-opioid pain management and making Better Pain Management, Possible. Guided by science, and a patient centered mindset, we are advancing innovative therapies aimed at addressing unmet needs across acute and chronic pain pathways. By leveraging novel delivery technologies and our expertise in musculoskeletal pain and pain adjacencies, our goal is to expand treatment options that can potentially improve outcomes for patients while reducing reliance on opioids.

Our growing pipeline builds on our legacy of products for pain while investigating in therapies like gene therapy. By advancing both established and emerging therapeutic approaches, we remain committed to delivering pain management treatment where it matters most.

Product
Target
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Line Extensions
ZILRETTA® (triamcinolone acetonide)
Knee OA
Shoulder OA
ioveraº®
Knee OA
Spasticity
EXPAREL® (bupivacaine liposome)
Post-Surgical Pain
Pediatric 0 to <6
Innovative Pipeline
PCRX-201*
Knee OA
PCRX-2002*
Post-Surgical Pain
PCRX-1001*
Canine OA
PCRX-1002*
Dry Eye Disease
PCRX-1003*
Degenerative Disc Disease

*Investigational products. Safety and Efficacy have not been established.

A woman with long gray hair sits on an open-air bus, gazing into the distance.
A woman with long gray hair sits on an open-air bus, gazing into the distance.

Better
is Possible.

Let’s innovate together

Collaboration drives progress, and we’re proud to work with organizations that share our vision for advancing pain management.

View partnership opportunities